Tricia Neuman
Newly-approved Alzheimer’s drug Leqembi slows mental decline — but high cost poses multi-billion dollar challenge for Medicare
The FDA has just granted traditional approval to Leqembi (lecanemab), an anti-amyloid monoclonal antibody treatment for Alzheimer’s disease, after granting ...
